Jennifer Good
Ms. Good has served as a member of our Board of Directors since June 2019. She is currently the President and Chief Executive Officer of Trevi Therapeutics, a biopharmaceutical company developing nalbuphine ER to treat serious neurologically mediated conditions, which she co-founded in March 2011. Previously, Ms. Good worked at Penwest Pharmaceuticals from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, and led the company through its transition from development-stage into a revenue-generating entity. Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. She has also served as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s ataxia, since 2011, and is the Treasurer for a nonprofit organization, Newtown Youth & Family Services, which provides mental health services and programs to support the community. Ms. Good holds her BBA in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.